Press Release

BioTime Acquires Asterias, Creating Leading Cell Therapy Company

March 13, 2019

Palo Alto – March 13, 2019 – Cooley advised BioTime on its acquisition of Asterias Biotherapeutics. Partner Tali Sealman led the Cooley team advising BioTime on the transaction. 

In connection with the acquisition, BioTime will advance three clinical stage product candidates for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. 

“This acquisition is a key step in our plan to turn BioTime into a pioneering and leading cell therapy company, with an innovative and diversified pipeline which we believe can significantly impact disease areas with groundbreaking therapeutic approaches,” Brian M. Culley, CEO of BioTime, said in a statement. “Importantly, we expect to enjoy significant financial synergies from this merger, as we already have a [current good manufacturing practice] manufacturing facility in Jerusalem, Israel, which has successfully produced our projected needs for the next clinical trial of OpRegen and which now can turn to process development and scale-up activities for the former Asterias assets.”

Headquartered in Alameda, California, BioTime’s securities trade on the New York Stock Exchange and the Tel Aviv Stock Exchange under the symbol “BTX.” 

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,000+ lawyers across 14 offices in the United States, China and Europe.


This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.